CytoMed Therapeutics Limited (GDTC) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
CytoMed Therapeutics Limited has released its unaudited interim condensed consolidated financial statements for the six months ended June 30, 2023 and 2024, revealing a loss for the period. The company experienced a decrease in total comprehensive loss from S$2,224,461 in 2023 to S$1,083,150 in 2024, with corresponding losses per share of S$0.22 and S$0.09 respectively. Key financial figures include research expenses and other operating losses, alongside revenue and operating income data for the concerned periods.
For further insights into GDTC stock, check out TipRanks’ Stock Analysis page.
